Drug Eluting Balloons Market Size was valued at USD 0.61 Billion in 2023. The Drug Eluting Balloons Market industry is projected to grow from USD 0.66 Billion in 2024 to USD 1.1 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2024 - 2032). Increasing demand for cath labs and favorable reimbursement policies are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The increasing prevalence of coronary artery disease and diabetes is likely to drive market CAGR in the drug eluting balloon over the forecast period. Drug-eluting balloons are angioplasty balloons that play an important role in the treatment of coronary heart disease. The high prevalence of coronary artery disease is likely to increase demand for angioplasty and other therapies, hence driving market expansion. According to the World Health Organization (WHO), coronary heart disease kills approximately 3.8 million men and 4.4 million women each year. Furthermore, the number of fatalities between the ages of 15 and 59 is estimated to reach 1332 million, with an additional 5825 million occurring after the age of 60.
Additionally, diabetes can damage blood vessels and neurons in the heart, which can lead to cardiovascular disease. As a result, the increasing prevalence of diabetes is likely to drive growth in the medication-eluting balloon market throughout the forecast period. For example, according to the World Health Organization's October 2018 report, diabetes causes approximately 1.6 million deaths worldwide. According to the Centers for Disease Control and Prevention, 537 million adults (20-79 years old) worldwide had diabetes in 2021, accounting for one in every ten people. China has the world's biggest number of diabetics, with over 141 million individuals suffering from the condition. By 2045, China is expected to have over 174 million diabetics.
In addition, according to the Centers for Disease Control and Prevention, the highest prevalence of diagnosed diabetes in 2019 was among American Indians and Alaska Natives (14.5%), followed by non-Hispanic Blacks (12.1%), people of Hispanic origin (11.8%), non-Hispanic Asians (9.5%), and non-Hispanic Whites. According to the World Health Organization, 3.1 million persons aged 20 and up, or 10.8% of all adults in the United States with diabetes, began using insulin within a year of being diagnosed. Thus driving the Drug Eluting Balloons Market revenue.
The Drug Eluting Balloons Market segmentation, based on Product, includes Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon and Others. In 2023, the Peripheral Drug Eluting Balloon category accounted for 72.64% of the global market, the biggest share. The American Heart Association's 2021 report addresses peripheral artery disease (PAD), which affects over 200 million people worldwide and has been associated with high mortality and morbidity. The aging of the global population is likely to result in an increase in PAD instances in the future. According to the statistics, the number of PADs is increasing at a faster rate, which is driving market expansion.
Figure 1: Drug Eluting Balloons Market, by Product, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Drug Eluting Balloons Market segmentation, based on Technology, includes Paccocath, FreePac, TransPax, EnduraCoat, and Others. In 2023, the TransPax category continued to dominate the market share. TransPax coating has balanced hydrophobic and hydrophilic characteristics, allowing the balloon to deliver an adequate therapeutic dose of Paclitaxel while reducing systemic loss.
The Drug Eluting Balloons Market segmentation, based on End-user, includes Hospitals and Ambulatory Surgery Centers, Cath Labs, and Others. The Hospitals and Ambulatory Surgery Centers category maintained a dominant market share in 2023, owing to an increase in in-patient admissions to hospitals for catheterization treatments, as well as a growing desire for less invasive procedures, which is expected to drive market demand. The increasing prevalence of vascular and urological problems, arrhythmia, and other conditions, as well as the availability of highly qualified medical and healthcare professionals, are some of the factors driving market growth.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America dominated the Drug Eluting Balloons Market in 2023, accounting for 45.80%. Several factors contribute to North America's considerable market share, including the availability of a variety of major manufacturers, the introduction of new, technologically advanced devices, and favorable reimbursement policies. The American Heart Association estimates that over 500,000 percutaneous coronary treatments, including percutaneous transluminal coronary interventions, are performed annually in the United States. Furthermore, increased government spending on health care in the United States is driving market growth.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: DRUG ELUTING BALLOONS MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Drug Eluting Balloons Market accounts for the second-largest market share. This is due to an increasing prevalence of cardiovascular diseases such as coronary artery disease, heart valve disease, arrhythmia, heart failure, peripheral disorders, and renal failure, among others. Further, the German Drug Eluting Balloons Market held the largest market share, and the UK Drug Eluting Balloons Market was the fastest-growing market in the European region.
The Asia-Pacific Drug Eluting Balloons Market is expected to grow at the fastest CAGR from 2024 to 2032. This can be attributed to rising healthcare costs and an increase in the prevalence of cardiovascular diseases. Moreover, China’s Drug Eluting Balloons Market held the largest market share, and the Indian Drug Eluting Balloons Market was the fastest-growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Drug Eluting Balloons Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Global Drug Eluting Balloons industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Global Drug Eluting Balloons industry to benefit clients and increase the market sector. In recent years, the Global Drug Eluting Balloons industry has offered some of the most significant advantages to medicine. Major players in the Drug Eluting Balloons Market, including Bayer AG, Medtronic, B. Braun Melsungen AG, Cook Medical, Inc., Boston Scientific Corporation and others, are attempting to increase market demand by investing in research and development operations.
Medtronic plc is an Irish medical device corporation. The company's operational and management offices are in Minneapolis, Minnesota, while its legal headquarters are in Ireland, following its 2015 acquisition of Irish-based Covidien. While it is based in the United States, it operates in over 150 countries and employs over 90,000 people. It creates and manufactures healthcare technologies and treatments. In July 2021, Medtronic plc introduced the Prevail™ Drug-Coated Balloon (DCB) Catheter, the next-generation catheter in Europe. It uses fast medication absorption to treat restricted or blocked coronary arteries in patients with coronary artery disease.
Boston Scientific Corporation is a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, such as interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynecology. Boston Scientific is widely recognized for developing the Taxus Stent, a drug-eluting stent used to unblock clogged arteries. Cameron Health was fully acquired in June 2012, and the firm became well-known for delivering a minimally invasive implantable cardioverter-defibrillator (ICD) known as the EMBLEM subcutaneous implantable defibrillator (S-ICD). In November 2020, The FDA approved Boston Scientific's Ranger Drug-Coated Balloon. These catheters are used to treat patients with superficial femoral artery (SFA) and proximal popliteal artery peripheral vascular disease (PAD). This approval gives the company an advantage over its competitors in the market for drug-eluting balloon catheters.
In July 2021, Medtronic Plc. began marketing the Prevail drug-coated balloon (DCB) catheter in Europe after it received CE (Conformité Européenne) certification. Patients with coronary artery disease who have blocked or narrowed coronary arteries are treated with the currently available coronary DCB, Prevail DCB, during percutaneous coronary intervention (PCI) procedures (CAD). During the catheter-based operation, the balloon inflate inside the artery, delivering the drug to the arterial tissue, where it is absorbed. The Prevail DCB uses paclitaxel, a fast-absorbing drug, to treat de novo lesions, minor vascular disease, and in-stent restenosis. Because a permanent implant is not required, DCB angioplasty is commonly used when drug-eluting stent (DES) implantation is not feasible or technically problematic.
In August 2022, BD announced the start of a first-in-human prevision trial of the peripheral sirolimus drug-coated balloon (DCB) to investigate its safety and efficacy. The trials aimed to assess sirolimus' potential as a future therapy option for people suffering from Peripheral Artery Disease (PAD).
In October 2023, Cordis, a global leader in the research and manufacturing of interventional cardiovascular and endovascular technologies, has announced the purchase of MedAlliance, a Swiss producer of drug-eluting balloon technology. The acquisition is expected to strengthen the company's coronary and peripheral vascular product portfolios.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.61 Billion |
| Market Size 2024 | USD 0.66 Billion |
| Market Size 2032 | USD 1.1 Billion |
| Compound Annual Growth Rate (CAGR) | 7.50% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Technology, End-user and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Â Bayer AG, Medtronic, B. Braun Melsungen AG, Cook Medical, Inc., Boston Scientific Corporation, Becton, Dickson and Company, EuroCor, Terumo Corporation, Koninklijke Philips N.V. |
| Key Market Opportunities | ·        The increasing number of treatment options |
| Key Market Dynamics | ·        Growing prevalence of peripheral and cardiovascular diseases. |
Frequently Asked Questions (FAQ) :
The Drug Eluting Balloons Market size was valued at USD 0.61 Billion in 2023.
The global market is projected to grow at a CAGR of 7.50% from 2024 to 2032.
North America had the largest share in the global market
The key players in the market are Bayer AG, Medtronic, B. Braun Melsungen AG, Cook Medical, Inc., and Boston Scientific Corporation.
The Hospitals and Ambulatory Surgery Centers category dominated the market in 2023.
The Peripheral Drug Eluting Balloon category had the largest share of the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
